MiR-29 promotes ovarian carcinoma cell proliferation through the PTEN pathway

The objective of this study was to investigate the role of miR-29 in ovarian carcinoma progression. Cell proliferation was measured with a cell counter. mRNA expression of miR-29, phosphatase and tensin homolog (PTEN), and proliferating cell nuclear antigen (PCNA) was measured by RT-PCR. Protein expression was detected by Western blot. The results demonstrated that miR-29 expression was upregulated in ovarian carcinoma and that miR-29 promoted cell proliferation. Consistently, miR-29 silencing decreased ovarian carcinoma cell proliferation. Mechanistically, we found PTEN expression was decreased following miR-29 overexpression and PTEN expression was increased following miR-29 silencing. Importantly, overexpression of PTEN was sufficient to inhibit ovarian carcinoma cell proliferation, demonstrating a key role for PTEN downstream of miR-29. Therefore, our study highlights the miR-29-PTEN pathway as a critical mediator of ovarian cancer cell proliferation, providing a new therapeutic target for patients with ovarian carcinoma.

Ovarian carcinoma; MiR-29; PTEN; Cell proliferation.

[1] Munksgaard P. S., Blaakaer J.: “The association between en-dometriosis and ovarian cancer: A review of histological, genetic and molecular alterations”. Gynecol. Oncol., 2012, 124, 164-169.

[2] Jelovac D., Armstrong D. K.: “Recent progress in the diagnosis and treatment of ovarian cancer”. Ca. Cancer J. Clin., 2011, 61, 183-203.

[3] McGuire W. P., Hoskins W. J., Brady M. F., Kucera P. R., Partridge E. E., Look K. Y., Clarke-Pearson D. L., Davidson M.: “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer”. the New England Journal of Medicine, 1996, 3341-6.

[4] Gaál Z., Oláh E.: “[MicroRNAs and their role in malignant hematologic diseases]”. Orv. Hetil., 2013, 153, 2051-2059.

[5] Lin S., Pan L., Guo S., Wu J., Jin L., Wang J., et al.: “Prognos-tic Role of MicroRNA-181a/b in Hematological Malignancies: A Meta-Analysis”. Plos one, 2013, 8, e59532.

[6] Kalinowski F. C., Brown R. A. M., Ganda C., Giles K. M., Epis M. R., Horsham J., et al.: “microRNA-7: A tumor suppressor miRNA with therapeutic potential”. the International Journal of Biochemistry & Cell Biology, 2014, 54, 312-317.

[7] Wu Z., Huang X., Huang X., Zou Q., Guo Y.: “The inhibitory role of MiR-29a in growth of breast cancer cells”. J. Exp. Clin. Cancer Res., 2013, 32, 98.

[8] Lv M., Zhong Z., Huang M., Tian Q., Jiang R., Chen J.: “IncRNA H19 regulates epithelial-mesenchymal transition and metastasis of bladder cancer by miR-29ab-3p as competing endogenous RNA”. Biochim. Biophys. Acta Mol cell res, 2017, 1864, 1887-1899.

[9] Kwon J. J., Willy J. A., Quirin K. A., Wek R. C., Korc M., Yin X. M., et al.: “Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential”. Oncotarget, 2016, 7, 71635-71650.

[10] Boosani C. S., Agrawal D. K.: “PTEN modulators: a patent review”. Expert Opinion on Therapeutic Patents, 2013, 23, 569-580.

[11] Gao Z., Wang J., Chen D., Ma X., Wu Y., Tang Z., et al.: “Long non-coding RNA GAS5 suppresses pancreatic cancer metastasis through modulating miR-32-5p/PTEN axis”. Cell & Bioscience, 2017, 7.

[12] Wang P., Guan Q., Zhou D., Yu Z., Song Y., Qiu W.: “miR-21 Inhibitors Modulate Biological Functions of Gastric Cancer Cells via PTEN/PI3K/mTOR Pathway”. Dna Cell Biol., 2018, 37, 38-45.

[13] Guarneri V., Piacentini F., Barbieri E., Conte P. F.: “Achievements and unmet needs in the management of advanced ovarian cancer”. Gynecol. Oncol., 2010, 117, 152-158.

[14] Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A., et al.: “Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer”. J. Clin. Oncol., 2008, 26, 890-896.

[15] ten Bokkel Huinink W., Lane S. R., Ross G. A.: “Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma”. Ann. Oncol., 2004, 15, 100-103.

[16] Rose P. G., Blessing J. A., Mayer A. R., Homesley H. D.: “Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.”. J. Clin. Oncol., 1998, 16, 405-410.

[17] Yang X., Liu F., Zhang Y., Wang L., Cheng Y.: “Cold-responsive miRNAs and their target genes in the wild eggplant species Solanum aculeatissimum”. Bmc Genomics, 2017, 18.

[18] Farina F. M., Inguscio A., Kunderfranco P., Cortesi A., Elia L., Quintavalle M.: “MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines”. Cell Death & Disease, 2017, 8, e2890-e2890.

[19] Muluhngwi P., Alizadeh-Rad N., Vittitow S., Kalbfleisch T., Klinge C.: “The miR-29a transcriptome in endocrine-sensitive and resistant breast cancer cells”. Sci. Rep., 2017, 7, 5205.

[20] To S. K. Y., Mak A. S. C., Eva Fung Y. M., Che C., Li S., Deng W., et al.: “β-catenin downregulates Dicer to promote ovarian cancer metastasis”. Oncogene, 2017, 36, 5927-5938.

[21] Chen L., Zhang S., Wu J., Cui J., Zhong L., Zeng L., et al.: “cir-cRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29a family”. Oncogene, 2017, 36, 4551.

[22] Wang X., Liu S., Cao L., Zhang T., Yue D., Wang L., et al.: “miR-29aa-3p suppresses cell proliferation and migration by downregu-lating IGF1R in hepatocellular carcinoma”. Oncotarget, 2017, 8, 86592.

[23] Shi C., Ren L., Sun C., Lin Y., Bian X., Zhou X., et al.: “miR-29aa/b/c function as invasion suppressors for gliomas by targeting CDC42 and predict the prognosis of patients”. Br. J. Cancer, 2017, 117, 1036.

[24] Li L., Zhu X., Shou T., Yang L., Cheng X., Wang J., et al.:“MicroRNA-28 promotes cell proliferation and invasion in gastric cancer via the PTEN/PI3K/AKT signalling pathway”. Mol. Med. Rep., 2017, 17, 4003-4010

[25] Li J., Li C., Li H., Zhang T., Hao X., Chang J., et al.: “MicroRNA-30a-5p suppresses tumor cell proliferation of human renal cancer via the MTDH/PTEN/AKT pathway”. Int. J. Mol. Med., 2018, 41, 1021-1029.